Revolutionising cell and gene therapy with polyNaut® nanovesicles

ViaNautis is transforming cell and gene therapy with polyNaut® nanovesicles (PNVs), a modular, non-viral delivery system that enables precise, plug-and-play targeting to cells in the central nervous system, lung, and immune system.

With broad payload flexibility, good tolerability and simplified, scalable manufacturing, ViaNautis is making safe, shelf-stable and re-dosable genetic therapies accessible to patients.

Latest News & Events

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines

Multi-year collaboration will use ViaNautis’ non-immunogenic polyNaut® nanovesicles that precisely target specific tissues and cell types.

ViaNautis Appoints Ray Jupp as Chief Scientific Officer

In The News

ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of genetic therapies, today announces the appointment of Dr Ray Jupp as…

ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

In The News

ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Adi Hoess as…

ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors

In The News

ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Steven M. Altschuler…

ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines

Press Releases

– ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet…

SomaServe- successful closing of £2m late seed funding round

In The News

SomaServe Ltd, a pioneer in nanomedicines for crossing biological barriers today announced that it has completed a highly successful, oversubscribed late seed funding of £2.1m…

View All News & Events